ArticleEmerging infectious diseases2010
Effects of pneumococcal conjugate vaccine 2 years after its introduction, the Netherlands.
Article in Emerging infectious diseases, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 53 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
53 citing papers in PubMed, 3 syntheses or guidelines pooled it, 162 citations in OpenAlex.
- Cost effectiveness of the new pneumococcal vaccines: a systematic review of European studies.PharmacoEconomics · 2014Pooled it
- Systematic review of the effect of pneumococcal conjugate vaccine dosing schedules on vaccine-type invasive pneumococcal disease among young children.The Pediatric infectious disease journal · 2014Pooled it
- Systematic review of the indirect effect of pneumococcal conjugate vaccine dosing schedules on pneumococcal disease and colonization.The Pediatric infectious disease journal · 2014Pooled it
- Differential B-cell memory around the 11-month booster in children vaccinated with a 10- or 13-valent pneumococcal conjugate vaccine.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2015Trial
- Trial
- Salivary immune responses to the 7-valent pneumococcal conjugate vaccine in the first 2 years of life.PloS one · 2012Trial
- Effects of community-wide vaccination with PCV-7 on pneumococcal nasopharyngeal carriage in the Gambia: a cluster-randomized trial.PLoS medicine · 2011Trial
- Article
- Investigating two decades ofMicrobial genomics · 2025Article
- Implications of Cross-Reactivity and Cross-Protection for Pneumococcal Vaccine Development.Vaccines · 2024Review
- Evolution of pneumococcal serotype epidemiology in Botswana following introduction of 13-valent pneumococcal conjugate vaccine.PloS one · 2022Article
- Estimating the Impact of Switching from a Lower to Higher Valent Pneumococcal Conjugate Vaccine in Colombia, Finland, and The Netherlands: A Cost-Effectiveness Analysis.Infectious diseases and therapy · 2020Article
- Review
- Pneumococcal vaccine impacts on the population genomics of non-typeable Haemophilus influenzae.Microbial genomics · 2018Article
- Triptych of the Hermit Saints: pneumococcal polysaccharide vaccines for the elderly.Risk management and healthcare policy · 2018Review
- Current status and future directions of invasive pneumococcal diseases and prophylactic approaches to control them.Human vaccines & immunotherapeutics · 2018Review
- Potential impact of introducing the pneumococcal conjugate vaccine into national immunisation programmes: an economic-epidemiological analysis using data from India.BMJ global health · 2018Article
- Modeling the cost-effectiveness of infant vaccination with pneumococcal conjugate vaccines in Germany.The European journal of health economics : HEPAC : health economics in prevention and care · 2017Article
- Sex differences in invasive pneumococcal disease and the impact of pneumococcal conjugate vaccination in the Netherlands, 2004 to 2015.Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
In the Netherlands, the 7-valent pneumococcal conjugate vaccine (PCV-7) was implemented in a 3+1-dose schedule in the national immunization program for infants born after April 1, 2006. To assess the vaccine's effectiveness, we compared disease incidence before and after vaccine implementation (June 2004-June 2006 and June 2006-June 2008, respectively). We serotyped 2,552 invasive pneumococcal isolates from throughout the Netherlands, covering 25% of the country's population. Clinical characteristics were extracted from hospital records. After June 2006, vaccine-serotype invasive pneumococcal disease (IPD) decreased 90% (95% confidence interval [CI] 68%-97%) in children age eligible for PCV-7; simultaneously, however, non-vaccine-serotype IPD increased by 71% (not significant), resulting in a 44% total net IPD reduction (95% CI 7%-66%). IPD rates did not change for other age groups. In the Netherlands, PCV-7 offered high protection against vaccine-serotype IPD in vaccinated children, but increases of non-vaccine-serotype IPD reduced net vaccine benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.